Fukushima Ryan sold $1.9M of TEM (indirect holdings)

Fukushima Ryan (CEO, Data) sold 30,846 indirectly-held shares of Tempus AI, Inc. (TEM) at an average of $62.71 ($62.12–$64.63, $1.93M total) across 4 trades on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fukushima Ryan
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEM
Bearish
medium confidence
Mentioned
$TEM
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMBearishLow
01

Why it matters

The disclosed sale provides fresh data for short‑term traders and long‑term investors assessing insider sentiment.

02

Market read

Primary source filing; modest insider sell may influence short‑term price action.

03

What to watch

The CEO retains 16,574 shares, representing a still‑substantial stake.

Relevance 5/10Novelty 6/10Timing: after market close on 2026‑09‑01

Background

Form 4 filing discloses insider transactions required by the SEC.

Company-level read

Ticker impact

$TEMBearishMedium confidence
Context

CEO Fukushima Ryan sold 30,846 shares for $1.93M via a 10b5‑1 plan.

Expected impact

possible modest downside of 2‑4% over the next few days

Evidence & confidence

The sale size is modest relative to market cap, but it is a direct insider disposition using a pre‑arranged plan, which traders often view as a slight bearish cue.

Market effects

Minimal impact on the broader AI/health‑tech sector.

No significant regional effect.

Limited to investors tracking insider activity.

Counterpoint

The sale may be purely portfolio rebalancing under a 10b5‑1 plan, not a negative signal.

Key entities

  • Tempus AI, Inc.

    AI‑driven healthcare data company listed on Nasdaq (TEM).

  • Fukushima Ryan

    CEO of Tempus AI, reporting an insider sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Tempus CEO Eric Lefkofsky: A Blood Draw Can Catch Returning Cancer 6 to 12 Months Before a Scan

Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.

$TEMMedAI 8/10

BTIG raises Tempus AI stock price target to $100 on data deals

BTIG raised its price target for Tempus AI (NASDAQ:TEM) to $100, citing strong quarterly results, raised guidance, and significant data deals, including a $200M agreement with Bristol Myers Squibb. The company reported 50% revenue growth and positive adjusted EBITDA. Other analysts also raised price targets, noting strong performance in data and diagnostics segments.

$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.